


Neurology
Speaker: Steven J. Smith, PhD
Alzheimer’s disease (AD) affects an estimated 24 million people worldwide. Although several medications have been FDA approved for the treatment of AD, there is still an urgent need for new therapies because like other forms of dementia, AD is complex and difficult to treat with one drug or intervention.
We know how important innovative, translatable animal models are to research that focuses on accelerating the identification of new drug targets and developing new therapies for diseases like AD. In this webinar we will introduce you to our novel AD mouse models, specifically our FAD4T mice and our Next-Generation AD models. We will also describe other exciting models available for researching various neurodegenerative diseases.
More information about blogs


Upcoming
The development of innovative therapeutics for renal diseases has moved from symptomatic treatments to disease-modifying treatments. To increase the translatability of preclinical data and drug discovery process, GemPharmatech has developed a comprehensive portfolio of kidney disease models recapitulating autoimmune, genetic and fibrotic pathologies for diverse renal disease research, supporting the evaluation of multiple therapeutic modalities, including antibodies, fusion proteins, gene therapy and small molecule compounds.
2026-09-22 00:00:00
11:00 AM ET
Yinlian Zhang, Ph.D.


On-Demand
Explore in vivo approaches for evaluating next-generation obesity therapeutics targeting GLP-1R, GIPR, and GCGR. This webinar presents pharmacology data from DIO mice, rat models, and humanized models spanning single, dual, and triple GLP‑1R, GIPR, and GCGR targets, providing practical insights into model selection, weight-loss efficacy benchmarking, and translational assessment of metabolic drug candidates.
2026-08-25 00:00:00
11:00 AM ET
Marina Gao, Ph.D.


On-Demand
Selecting the right humanized mouse model is one of the most consequential decisions in immuno-oncology (IO) drug development. The wrong model can mask safety liabilities, inflate efficacy estimates, and weaken the data supporting regulatory submissions. Join GemPharmatech for a data-driven webinar on how strategic humanized mouse model selection strengthens preclinical decision-making, sharpens translational relevance, and supports IND-enabling studies.
2026-07-30 00:00:00
11:00 AM ET
Xinjie Lian

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
